Cross-referencing clinical data
A pairing appears on this page only when a trial gave both ingredients together and measured the result. Hydrastine has none that clears that bar.
Stitching two separate single-ingredient studies into a pairing is the one thing this engine will not do. When a study of the combination itself holds up at source, it lands here with its citation.
No invented synergy. Where actives were studied on their own rather than together, the record shows each on its own evidence, never a combined effect no trial measured.
Research strength. Research strength says how much work stands behind the combination. It is never a product score.
Independent record. Every finding is cited to a named trial, dated, and never written by the brand.
20 pairings are live across the library today. Checked 20 July 2026.
No study gave these as a pair, so they are not in the card above. But the reason they belong together is settled biochemistry, not a guess, so it is worth knowing.
Both are isoquinoline alkaloids from the same root, and goldenseal extracts are conventionally standardised to both. They are chemically distinct: berberine is a quaternary protoberberine with a permanent positive charge, hydrastine is a phthalideisoquinoline that is not permanently charged. This difference drives quite different absorption behaviour. Data generated on berberine does not transfer to hydrastine, and the two should not be discussed interchangeably.
Practically no product sells isolated hydrastine. What is on the market is goldenseal root standardised to a stated hydrastine and berberine percentage. This matters because everything documented about goldenseal, including its interaction profile, was generated on the whole extract, not on hydrastine alone. Attribution to the single alkaloid is usually unwarranted.
Goldenseal is one of the better-documented botanical inhibitors of cytochrome P450 enzymes, notably CYP3A4 and CYP2D6, which together handle a large share of orally administered medicines. Silymarin has its own, generally weaker, effects on the same system. Combining two agents that both act on drug metabolism raises the chance of altering the handling of anything else taken alongside. Anyone on prescription medication should raise this with their prescriber rather than working it out from a label.
Grapefruit furanocoumarins irreversibly inactivate intestinal CYP3A4, and goldenseal alkaloids inhibit the same enzyme. Because the effects run in the same direction on a shared target, combining them compounds the effect on first-pass metabolism. The consequence is higher systemic exposure to co-administered CYP3A4 substrates. This is the single most practically important thing to know about goldenseal-type alkaloids.
Piperine is added to formulations precisely because it slows first-pass metabolism and raises systemic exposure to co-ingested compounds. Goldenseal alkaloids do the same thing through overlapping targets. Stacking two metabolic inhibitors in one product amplifies the effect on anything else in the gut at the same time, including prescription medicines. This is a flag rather than a benefit.
Hydrastine biosynthesis in the plant proceeds from tyrosine through dopamine and 4-hydroxyphenylacetaldehyde to norcoclaurine, and the decarboxylation steps require pyridoxal-5-phosphate. This is plant biochemistry and describes how the compound is made, not anything about what it does in a person taking it. It is included because it explains the alkaloid's structural family.
Nothing specific on file for Hydrastine. Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.These are the studies our verdict leans on, chosen from the 1 we read for Hydrastine. The full linked list is below.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.